by In2Pharma | Jul 31, 2020 | News
The Netherlands The Claims Regulation has been in force since 2012. All Member States submitted claims for botanicals (herbals) and non-botanicals (vitamins and minerals). These have been scientifically assessed by EFSA and subsequently endorsed by the European...
by In2Pharma | Jul 7, 2020 | News
The Netherlands On the basis of scientific conditions, the Medicines Evaluation Board (MEB) will draw up a list of medicines for which switching is undesirable. It will do this in the interests of patient safety. Medicines with the same active ingredient, dosage and...
by In2Pharma | Jun 11, 2020 | News
The Netherlands For safety reasons, the Medicines Evaluation Board portal was provisionally taken offline in January this year and unfortunately the MEB made the decision to close down the portal permanently. Due to the closure of the portal, the following services...
by In2Pharma | Jun 11, 2020 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy on Direct Healthcare Professional Communications (DHPCs) for medicinal products for human use. The update includes the following: “The marketing authorisation holder must attach one (or more)...
by In2Pharma | Mar 15, 2019 | News
The Netherlands Since February, all prescription medicines have a unique code and sealed packaging. The purpose of these safety features is to detect counterfeit medicines in the regular distribution channel. Any problem with the code or the seal can be reported...
